Atlas Genetics, a UK-based firm specializing in point-of-care in vitro diagnostics, is aiming to market its first products — a low-cost, ultra-rapid, cartridge-based testing system and associated nucleic acid test for Chlamydia trachomatis — with CE marking by the end of 2014, a company representative said recently.

Soon thereafter, Atlas aims to then commercialize a combined chlamydia/gonorrhea molecular assay both in Europe and the US, followed by tests for Trichomonas vaginalis, herpes simplex virus, syphilis, and HIV.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.